Join Dr. Pam Ling, a UCSF expert on vaping cessation, and Dr. Maya Vijayaraghavan, who specializes in vaping health implications, as they explore the intricate world of e-cigarettes. They discuss how to effectively communicate with patients about vaping and whether e-cigarettes can aid in quitting traditional cigarettes. The conversation also addresses the development of nicotine use disorders, resources for cessation, and the importance of personalized treatment plans. Tune in for invaluable insights into vaping and addiction medicine!

In this discussion, Dr. Al Garcia-Romeu, a prominent researcher at the Johns Hopkins Center for Psychedelic and Consciousness Research, sheds light on the transformative potential of hallucinogens. He delves into their mechanisms of action, focusing on psilocybin and its role in treating addiction and mental health disorders. Risks of unregulated use and the intricacies of psychedelic-assisted therapy are explored, alongside the legal landscape affecting these substances. The conversation emphasizes informed patient communication and the importance of ongoing research in this emerging field.

Maximize your treatment of alcohol-associated liver disease. Learn how to evaluate liver disease in patients with alcohol use disorder (AUD), choose AUD medications that are safe and effective, and identify patients who may be eligible for early liver transplantation. We’re joined by Dr. Lamia Haque, @lykhaque (Yale School of Medicine). We are thrilled to produce Season 3 with support and partnership from The American College of Academic Addiction Medicine (ACAAM)! Claim CME for this episode at curbsiders.vcuhealth.org! By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | Free CME! Show Segments Intro, disclaimer, guest bio 0:00  Guest one-liner 3:10 Case from Kashlak 6:30 Epidemiology of alcohol-associated liver disease (ALD) 7:40 How does alcohol affect the liver? 11:11 Spectrum of ALD 13:10 Risk factors for ALD 16:13 Evaluating for ALD 19:35 When to refer to hepatology 33:08 Medications for AUD in patients with ALD 37:00 Monitoring liver tests for naltrexone 44:27 Optimizing treatment for patients who continue drinking 47:18 ALD and liver transplantation 50:45 Post-transplant care 1:00:15 Take-home points 1:02:30 Outro 1:04:56 Credits Writer and Producer: Kenneth Morford, MD Show Notes: Kenneth Morford, MD Infographic and Cover Art: Natalie Stahl, MD, MPH Hosts: Carolyn Chan, MD. MHS and Kenneth Morford, MD Reviewer: Sarah Leyde, MD Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Lamia Haque, MD, MPH

Spark your learning! We cover clinical pearls from graduating addiction medicine fellows by covering ACAAM’s annual lighting round presentation.  Learn about tianeptine, buprenorphine starts in patients with acute hepatitis, vaccinations for persons who inject drugs, and more!  We are thrilled to produce Season 3 with support and partnership from The American College of Academic Addiction Medicine (ACAAM)!  Claim CME for this episode at curbsiders.vcuhealth.org! Listening to this episode and completing CME, can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | Free CME! Credits Producer, Show Notes, Infographics: Carolyn Chan Hosts: Carolyn Chan, MD. MHS, Shawn Cohen, MD, Kenneth Morford, MD, Natalie Stahl, MD MPHS Reviewer: Sarah Leyde, MD Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Show Segments 00:00 Intro, disclaimer 03:00 Picks of the week 07:00 Buprenorphine and hepatitis 16:30 Ketamine for withdrawal 24:00 Hepatitis B 28:20 Tianeptine 35:30 Hepatitis C treatment 39:00 PETH 47:40 Unintended phenobarbital consequences 53:40 TBI and overdose risk 58:00 Outro

Expand your practice to include wound care for xylazine-related wounds and learn how to talk to your patients about harm reduction for xylazine. We are joined by Dr. Raagini Jawa (@Raaginizzle, UPMC) and Tehya Johnson, NP (@TehyaRJohnson, Boston Health Care for the Homeless).  We are thrilled to produce Season 3 with support and partnership from The American College of Academic Addiction Medicine (ACAAM)!  Claim CME for this episode at curbsiders.vcuhealth.org! By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | Free CME! Credits Show notes, infographics, cover art, writer and producer:  Zina Huxley-Reicher, MD  Hosts: Carolyn Chan, MD. MHS, Zina Huxley-Reicher, MD and Shawn Cohen, MD  Reviewer: Payel Jhoom Roy, MD, MSc Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guests: Raagini Jawa, MD MPH and Tehya Johnson, NP  Show Segments Intro, disclaimer, guest bios - 01:42  Guest one-liners - 03:22 Case from Kashlak - 7:56 Definition of xylazine, overview of xylazine in the drug supply and experience of use - 08:38 Xylazine test strips and other harm reduction strategies - 15:48 Natural history of xylazine wounds - 19:15 Creating a welcoming wound care environment - 21:05 Red flag symptoms indicating need for oral antibiotics and higher levels of care - 26:18 Steps for wound care - 33:27 Frequency of wound care - 46:16 Pain control in the setting of dressing changes - 51:01 Route switching, harm reduction around injecting at the site of the wound - 52:20 When to refer to other wound care specialists/plastic surgery - 55:00 Take home points - 57:05 Outro - 1:00:17 

Dr. Ruth Potee and Dr. David Frank discuss methadone treatment, intake process, personal impact, requirements at OTP, dosing, take-home doses, and interacting with OTP as a PCP. They emphasize clinicians' role in improving access to methadone treatment, advocating for policy changes, and the importance of harm reduction in addiction medicine.

Dr. Melissa Weimer from Yale University discusses treating opioid use disorder in the fentanyl era. Topics include methadone and buprenorphine initiation changes, pitfalls, precipitated withdrawal, dosing strategies, and individualized care. Learn how to provide person-centered care and address challenges in addiction medicine.

Dr. Alex Walley, a medical doctor and researcher specializing in opioid overdose treatment and prevention, discusses various topics including optimal ways to respond to hospital overdoses, ideal doses of naloxone, counseling patients on overdose response and prevention, and the importance of good Samaritan laws in overdose situations.

Amelia Goff FNP and Eleasa Sokolski, MD join the hosts to discuss low-dose buprenorphine starts for opioid use disorder, covering physiology, protocols, and troubleshooting challenges faced by patients. They also talk about different formulations of buprenorphine, counseling patients, and considerations for specific patient populations. The episode provides valuable insights on outpatient low dose starts and concludes with key takeaways.

Gain insight into how racialized US drug policies, the War on Drugs, and media portrayals of substance use impact our patients in ongoing ways. Learn how you can take action and intentionally promote equity as a clinician! We’re joined by Dr Myra Mathis, @DrMyraMathis (University of Rochester Medical Center) Claim free CME for this episode at curbsiders.vcuhealth.org! By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Credits Producer, Writer, Show notes, Infographic, Cover Art: Katherine Mullins, MD Hosts: Carolyn Chan, MD, MHS and Katherine Mullins, MD Reviewer: Kento Sonoda, MD Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Myra Mathis, MD Show Segments Intro 0:00  Disclaimer 2:00   Guest bio 3:30   Episode Pearls 4:36   Guest One-Liner and Intro 5:15  Definitions (race and racism) 7:13   The War on Drugs 9:09   AntiDrug Abuse Act of 1986 11:47   Fair Sentencing Act of 2010 14:10   Policy in the Fentanyl Era 15:15   Mass Incarceration + Downstream Effects 17:30   Media Portrayals 19:24   Current Treatment Landscape 23:29   Disparities in Overdose Deaths 25:50   The Parallel System of White Supremacy 26:41   The Clinician’s Role: Advocacy on the Policy Level 27:40   The Clinician’s Role: Advocacy on the Clinic Level 29:22   Harm reduction 30:25 - 32:44